Compare VIRT & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VIRT | TARS |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.7B |
| IPO Year | 2014 | 2020 |
| Metric | VIRT | TARS |
|---|---|---|
| Price | $49.99 | $65.58 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $45.60 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 1.3M | 449.1K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | ★ 72.73 | 48.21 |
| EPS | ★ 1.99 | N/A |
| Revenue | ★ $3,632,118,000.00 | $451,360,000.00 |
| Revenue This Year | N/A | $56.43 |
| Revenue Next Year | $1.34 | $30.19 |
| P/E Ratio | $25.37 | ★ N/A |
| Revenue Growth | 26.25 | ★ 146.71 |
| 52 Week Low | $31.55 | $38.51 |
| 52 Week High | $52.21 | $85.25 |
| Indicator | VIRT | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 58.43 | 48.15 |
| Support Level | $32.61 | $61.24 |
| Resistance Level | $52.18 | $67.70 |
| Average True Range (ATR) | 1.71 | 3.07 |
| MACD | -0.21 | 0.19 |
| Stochastic Oscillator | 60.67 | 55.01 |
Virtu Financial Inc is a financial firm that leverages technology to deliver liquidity to the world-wide markets and transparent trading solutions to its clients. The company's operating segment includes Market Making; and Execution Services. The non-operating segment of the company includes the Corporate segment. The company generates maximum revenue from the market-making segment. The Market Making segment principally consists of market-making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Geographically, it derives a majority of its revenue from the United States and also has a presence in Ireland and Other Countries.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.